Skip to content

Study · Non-randomized trial · 2012

3 results

Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.

Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ

The Journal of clinical endocrinology and metabolism25 Jan 2012Cited by 72 (Europe PMC)

PMID22278424 (opens in a new tab)DOI10.1210/jc.2011-2603 (opens in a new tab)PepBankPUB-22278424
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In active acromegaly, adding pegvisomant to cabergoline reduced IGF-I from 389 ± 192 to 229 ± 101 ng/ml.

    In plain wordsIn active acromegaly, adding pegvisomant reduced IGF-I compared with cabergoline alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-I after add-on pegvisomant
    Study

    n: not reported in source

    Comparator
    Cabergoline alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg daily · 12 wkAs given in this study (human).

    Measurements

    IGF-I mean
    389 ng/ml
    cabergoline alone
    IGF-I standard deviation
    192 ng/ml
    cabergoline alone
    IGF-I mean
    229 ng/ml
    cabergoline plus pegvisomant
    IGF-I standard deviation
    101 ng/ml
    cabergoline plus pegvisomant

    Source sentences

    Summary
    The addition of 10 mg pegvisomant daily for 12 wk significantly reduced IGF-I (389 ± 192 ng/ml cabergoline vs. 229 ± 101 ng/ml combination), and 68% achieved a normal IGF-I.
    1 context sentence
    Summary · context
    Twenty-four patients were recruited into a United Kingdom, multicenter, open-label, prospective clinical trial.
  2. 02HumanNon-randomized trialEfficacy outcome

    In active acromegaly, 26% maintained normal IGF-I on pegvisomant 12 weeks after cabergoline withdrawal.

    In plain wordsIn active acromegaly, 26% maintained normal IGF-I on pegvisomant alone at 12 weeks after cabergoline withdrawal.

    Peptide
    Pegvisomant
    Outcome
    Not applicableNormal IGF-I on pegvisomant monotherapy
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg dailyAs given in this study (human).

    Measurements

    Patients with IGF-I in reference range
    26%
    12 weeks after cabergoline withdrawal, on pegvisomant 10 mg

    Source sentences

    Summary
    Twelve weeks after cabergoline withdrawal, while continuing to receive pegvisomant 10 mg, only 26% of patients maintained an IGF-I within the reference range (229 ± 101 ng/ml combination vs. 305 ± 177 ng/ml pegvisomant).
    1 context sentence
    Summary · context
    Twenty-four patients were recruited into a United Kingdom, multicenter, open-label, prospective clinical trial.
  3. 03HumanNon-randomized trialEfficacy outcome

    In active acromegaly, IGF-I was 305 ± 177 ng/ml during pegvisomant monotherapy 12 weeks after cabergoline withdrawal.

    In plain wordsIn active acromegaly, IGF-I was 305 ± 177 ng/ml on pegvisomant alone 12 weeks after cabergoline withdrawal.

    Peptide
    Pegvisomant
    Outcome
    Not applicableIGF-I on pegvisomant monotherapy
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mgAs given in this study (human).

    Measurements

    IGF-I
    305 ng/ml
    12 weeks after cabergoline withdrawal
    IGF-I standard deviation
    177 ng/ml
    12 weeks after cabergoline withdrawal

    Source sentences

    Summary
    Twelve weeks after cabergoline withdrawal, while continuing to receive pegvisomant 10 mg, only 26% of patients maintained an IGF-I within the reference range (229 ± 101 ng/ml combination vs. 305 ± 177 ng/ml pegvisomant).
    1 context sentence
    Summary · context
    Twenty-four patients were recruited into a United Kingdom, multicenter, open-label, prospective clinical trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.